Role of chemotherapy in malignant bone tumors | ||||
| Benha Medical Journal | ||||
| Article 10, Volume 38, special issue (Orthopedic Surgery), September 2021, Page 108-120 PDF (524.67 K) | ||||
| Document Type: Review Article | ||||
| DOI: 10.21608/bmfj.2021.21014.1190 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
George romnay tanus  1; Galal el din husein kazem2; mohamed anter mselhey3; mahmoud mostafa ibrahim4
| ||||
| 1ALEXANDRIA POLICE HOSP | ||||
| 2benha univ hosp | ||||
| 3benha univ hospital | ||||
| 4benha university hosp | ||||
| Abstract | ||||
| Background Osteosarcoma is the most frequent primary malignant bone tumor. In Europe and the United States, its prognosis has been greatly improved by the use of multimodal treatment, including preoperative and postoperative chemotherapy as well as surgery. In Japan, however, only a few clinical studies on osteosarcoma have been carried out. The aim of this study is To evaluate the efficacy of neoadjuvant chemotherapy on nonmetastatic, operable osteosarcoma arising in the extremities.Patients and methods A total of 124 patients were enrolled in this trial, and ultimately 113 patients were eligible, the Neoadjuvant Chemotherapy for Osteosarcoma (NECO) study, was conducted. Preoperative chemotherapy included high-dose methotrexate (HD-MTX), cisplatin (CDDP), and adriamycin (ADR). If the induction therapy was assessed as not effective, high-dose ifosfamide (IFO) was added to the chemotherapy regimen.Results The 5-year overall survival (OAS) and event-free survival (EFS) rates in the NECO study were 77.9% and 65.5%, respectively. A good histological response to the induction chemotherapy resulted in favorable OAS (78.7%). The patients assessed as poor histological responders with progressive disease after the induction chemotherapy exhibited comparable outcomes (OAS 89.5%, EFS 68.2%).Conclusion We analyzed the results of the intensive neoadjuvant chemotherapy and the effects of adding IFO on patients with osteosarcoma . The results suggest efficacy of the high-dose IFO addition to the standard three-drug chemotherapy regimen. However, a randomized clinical study is needed to establish the true impact of IFO on patients with osteosarcoma | ||||
| Keywords | ||||
| bone malignancy; chemotherapy; Malignant | ||||
|
Statistics Article View: 123 PDF Download: 329 |
||||
